Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the upcoming 45th Annual TD Cowen Health Care Conference. The company's presentation is scheduled for Tuesday, March 4, 2025, at 11:10 A.M. ET.
The event will feature a live webcast accessible through a direct link or via Madrigal's Investor Relations Events page. For those unable to attend the live presentation, a replay option will be made available following the event.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
In the trading session that priced this news, MDGL declined 4.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
